Clinical Trials Logo

Vitreoretinal Disease clinical trials

View clinical trials related to Vitreoretinal Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06429969 Recruiting - Clinical trials for Vitreoretinal Disease

Metabolomic Profile of Vitreoretinal Diseases: an NMR-Based Approach Using Vitreous.

NMR
Start date: January 17, 2024
Phase:
Study type: Observational

The goal of this observational study was to learn about metabolomics profiles in vitreoretinal diseases by nuclear magnetic resonance (NMR)using vitreous fluid. The main question it aimed to answer was abnormal biomarkers for common retinal diseases such as idiopathic macular hole(IMH), diabetic retinopathy(DR) and retinal detachment(RD). Participants would not be subjected to any intervention and the investigators would only collect preoperative information and remaining vitreous samples. The investigators divided the participants into groups with appropriate disease names based on the disease diagnosis, such as IMH group, DR group, and RD group. The MH group was used as a control group, investigators compared other groups to see the metabolomic abnormalities.

NCT ID: NCT06294613 Recruiting - Clinical trials for Vitreoretinal Disease

A Prospective, Open-label, Single-center, Study of the ACUSURGICAL Luca System for Treatment of Vitreoretinal Diseases

Start date: February 8, 2024
Phase: N/A
Study type: Interventional

Prospective, interventional, open-label, non-controlled, monocentric study in Belgium of Luca, of up to 7 evaluable subjects, undergoing vitreoretinal surgery to treat intravitreal hemorrhage and macular pucker. Only one eye per subject can be enrolled.

NCT ID: NCT00744666 Recruiting - Ocular Hypertension Clinical Trials

IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids

IVTA:PRE-TREAT
Start date: September 2008
Phase: Phase 4
Study type: Interventional

Intravitreal triamcinolone acetonide (IVTA) is a commonly employed treatment for various vitreoretinal disorders. However, approximately 23% to 50% of patients who receive IVTA develop ocular hypertension after the drug is injected into the eye. Similar to IVTA, topically administered corticosteroids eye drops result in ocular hypertension in approximately 33% of the population. It is unknown whether identifying patients who develop ocular hypertension from topical corticosteroids could be used to identify patients who are at risk for injectable IVTA. Therefore, the purpose of this study is to evaluate the efficacy of topical prednisolone 1% four times daily for one month as a screening test to reduce the incidence and severity of ocular hypertension after IVTA injection.